WAVEMAN · COMPANY

USNA · Usana Health Sciences Inc

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

USNA

Name: USANA HEALTH SCIENCES INC (USNA) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

USANA HEALTH SCIENCES INC

PHARMA & BIOTECH · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · CIK 0000896264

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$637.0K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+8.3%

XBRL, annual

NET MARGIN

1.2%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$637.0K over 180 days

-$250.6K over 90 days

below 57% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

83 funds added or opened last quarter

more than 58% of Pharma & Biotech

REVENUE

+8.3% year over year

more than 59% of Pharma & Biotech

MARGIN

1.2% net margin

more than 67% of Pharma & Biotech

BUYBACKS

$27.5M repurchased, FY to 2026-01-03

below 56% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$637.0K across 6 people in 180 days.

83 funds added or opened positions in the latest 13F quarter, of 139 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -52.8%

-52.8%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $637.0K sold by insiders over 180 days, 83 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, USANA HEALTH SCIENCES INC insiders sold a net $637.0K of stock across 117 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Neidig Brent

CHIEF COMMERCIAL OFFICER

SELL

2026-06-16

5,002.0

$97.3K

Neidig Brent

CHIEF COMMERCIAL OFFICER

SELL

2026-06-15

909.0

$18.2K

Neidig Brent

CHIEF COMMERCIAL OFFICER

SELL

2026-06-12

1,602.0

$32.3K

Jones Paul A.

CHIEF PEOPLE OFFICER

SELL

2026-06-08

5,561.0

$102.9K

Fleming John Turman

Director

SELL

2026-06-01

2,450.0

$43.9K

117 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 112 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Nantahala Capital Management, LLC

1,620,148.0 sh

$34.6M

BlackRock, Inc.

1,554,189.0 sh

$33.2M

PZENA INVESTMENT MANAGEMENT LLC

1,205,587.0 sh

$25.7M

RENAISSANCE TECHNOLOGIES LLC

958,520.0 sh

$20.5M

DIMENSIONAL FUND ADVISORS LP

837,426.0 sh

$17.9M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Acquirers Small and Micro Deep Value ETF

$273.5K POSITION · AS OF 2026-02-28

1.0%

Pzena Small Cap Value Fund

$939.8K POSITION · AS OF 2026-02-28

1.0%

ETC 6 Meridian Small Cap Equity ETF

$883.5K POSITION · AS OF 2026-02-28

0.7%

First Trust Active Factor Small Cap ETF

$323.0K POSITION · AS OF 2026-02-28

0.4%

Royce Quant Small-Cap Quality Value ETF

$69.4K POSITION · AS OF 2026-03-31

0.3%

iShares US Small Cap Value Factor ETF

$367.4K POSITION · AS OF 2026-03-31

0.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 5 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2026-01	2024-12	2023-12	2022-12
REVENUE	$925.3M	$854.5M	$921.0M	$998.6M
GROSS PROFIT	$724.4M	$693.3M	$744.3M	$804.7M
OPERATING INCOME	$37.4M	$66.3M	$93.1M	$107.6M
NET INCOME	$10.8M	$42.0M	$63.8M	$69.3M
EPS (DILUTED)	0.58	2.19	3.30	3.59
OPERATING CASH FLOW	$22.3M	$61.0M	$70.6M	$103.9M
CASH	$158.4M	$181.8M	$330.4M	$288.4M
BUYBACKS	$27.5M	$9.4M	$11.6M	$25.4M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE